Previous 10 | Next 10 |
Adverum Bio cut to market perform at SVB LeerinkAdverum Biotechnologies (ADVM) has gained ~3.8% in the premarket despite a downgrade by SVB Leerink to market perform from outperform. The price target of $5.00 per share implies ~28.2% upside to the last close.The cancella...
The anticipated impact on healthcare in a post-pandemic setup has led to contrasting views on two different healthcare providers: HCA Healthcare and LHC Group. Furthermore, several initiations are also included in today’s analyst action.HCA Healthcare downgraded at CitiCiti analysts Ra...
The following slide deck was published by Viracta Therapeutics, Inc. in conjunction with this event. For further details see: Viracta Therapeutics (VIRX) Presents At 20th Annual Needham Virtual Healthcare Conference - Slideshow
Viracta Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference PR Newswire SAN DIEGO , April 8, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated maligna...
XOMA Corporation ([[XOMA]] +20.5%) has gained more than a fifth of its value and if the rally holds, the stock could end up with its biggest one-day gain since September 2017.A few days ago, XOMA announced the purchase of potential future milestones and royalties linked to two clini...
Calling the company ‘an oncology diamond,’ Evercore ISI has initiated coverage on Viracta Therapeutics ([[VIRX]] +11.5%) with an outperform rating. Its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas underlies the firm’s thesis.The price target ...
Updated interim data provided by AstraZeneca (AZN) yesterday from its late-stage COVID-19 vaccine trial in the U.S., should address the data integrity issue, UBS wrote in a note. AstraZeneca ADRs are trading marginally up in before hours.The Analysts led by Michael Leuchten with a buy ra...
Pieris Pharmaceuticals PIRS +46% on collaboration with Seagen.Houston Wire & Cable Company HWCC +41% on being acquired by OmniCable for $5.30 per share.Cellect Biotechnology APOP +41% on a definitive merger agreement with Quoin Pharmaceuticals.Immutep Limited...
Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction Viracta to Receive $13.5 Million Upfront Cash Payment XOMA to Receive Economics on Two Clinical-Stage Partnered Programs PR Newswire SAN DIEGO and EMERYVILLE, Calif. , ...
Viracta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference PR Newswire SAN DIEGO , March 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, ...
News, Short Squeeze, Breakout and More Instantly...
Viracta Therapeutics Inc. Company Name:
VIRX Stock Symbol:
NASDAQ Market:
Viracta Therapeutics Inc. Website:
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Mi...
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Michael Faerm as Chief Financia...